Art. 10 Directive (EU) 2001/83

In forcesince 26 Jan 2007cited 111×
1.

By way of derogation from Article 8(3)(i), and without prejudice to the law relating to the protection of industrial and commercial property, the applicant shall not be required to provide the results of pre-clinical tests and of clinical trials if he can demonstrate that the medicinal product is a generic of a reference medicinal product which is or has been authorised under Article 6 for not less than eight years in a Member State or in the Community.

A generic medicinal product authorised pursuant to this provision shall not be placed on the market until ten years have elapsed from the initial authorisation of the reference product.

The first subparagraph shall also apply if the reference medicinal product was not authorised in the Member State in which the application for the generic medicinal product is submitted. In this case, the applicant shall indicate in the application form the name of the Member State in which the reference medicinal product is or has been authorised. At the request of the competent authority of the Member State in which the application is submitted, the competent authority of the other Member State shall transmit within a period of one month, a confirmation that the reference medicinal product is or has been authorised together with the full composition of the reference product and if necessary other relevant documentation.

The ten-year period referred to in the second subparagraph shall be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorisation holder obtains an authorisation for one or more new therapeutic indications which, during the scientific evaluation prior to their authorisation, are held to bring a significant clinical benefit in comparison with existing therapies.

2.

For the purposes of this Article:

(a)

‘reference medicinal product’ shall mean a medicinal product authorised under Article 6, in accordance with the provisions of Article 8;

(b)

‘generic medicinal product’ shall mean a medicinal product which has the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference medicinal product, and whose bioequivalence with the reference medicinal product has been demonstrated by appropriate bioavailability studies. The different salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives of an active substance shall be considered to be the same active substance, unless they differ significantly in properties with regard to safety and/or efficacy. In such cases, additional information providing proof of the safety and/or efficacy of the various salts, esters or derivatives of an authorised active substance must be supplied by the applicant. The various immediate-release oral pharmaceutical forms shall be considered to be one and the same pharmaceutical form. Bioavailability studies need not be required of the applicant if he can demonstrate that the generic medicinal product meets the relevant criteria as defined in the appropriate detailed guidelines.

3.

In cases where the medicinal product does not fall within the definition of a generic medicinal product as provided in paragraph 2(b) or where the bioequivalence cannot be demonstrated through bioavailability studies or in case of changes in the active substance(s), therapeutic indications, strength, pharmaceutical form or route of administration, vis-à-vis the reference medicinal product, the results of the appropriate pre-clinical tests or clinical trials shall be provided.

4.

Where a biological medicinal product which is similar to a reference biological product does not meet the conditions in the definition of generic medicinal products, owing to, in particular, differences relating to raw materials or differences in manufacturing processes of the biological medicinal product and the reference biological medicinal product, the results of appropriate pre-clinical tests or clinical trials relating to these conditions must be provided. The type and quantity of supplementary data to be provided must comply with the relevant criteria stated in Annex I and the related detailed guidelines. The results of other tests and trials from the reference medicinal product's dossier shall not be provided.

5.

In addition to the provisions laid down in paragraph 1, where an application is made for a new indication for a well-established substance, a non-cumulative period of one year of data exclusivity shall be granted, provided that significant pre-clinical or clinical studies were carried out in relation to the new indication.

6.

Conducting the necessary studies and trials with a view to the application of paragraphs 1, 2, 3 and 4 and the consequential practical requirements shall not be regarded as contrary to patent rights or to supplementary protection certificates for medicinal products.

The 10 that are cited most themselves, of 111.

  • Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…1636Law

    … 3, artikel 10, 10a, 10b og 11 eller artikel 32, stk. 5, i direktiv 2001/83/EF og bilag I hertil eller i artikel 9, stk. 4, i denne forordning. Navnlig underretter indehaveren af markedsføringstilladelsen straks agenturet og Kommissionen …

  • Directive (EU) 2004/272Lawamends

    Защитните срокове, предвидени в член 1, точка 8, с който се изменя член 10, параграф 1 от Директива 2001/83/EО, не се прилагат за …

  • Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…30369Law

    … в съответствие с член 14, параграф 11 от Регламент (ЕО) № 726/2004 или с член 10 от Директива 2001/83/ЕО, при подаване на заявление за издаване …

  • Judgment of the Court (Fifth Chamber), 23 October 2014. Olainfarm AS v Latvijas Republikas Veselības ministrija and Zāļu valsts aģentūra.Decisioninterprets

    In those circumstances, the Augstākās Tiesas Senāts (Senate of the Supreme Court), decided to stay the proceedings and to refer the following questions to the Court for a preliminary ruling: On a proper construction of Article 10 or of …

    23 Oct 2014 · 62013CJ0104

  • Judgment of the General Court (Seventh Chamber, Extended Composition) of 5 May 2021. Pharmaceutical Works Polpharma S.A. v European MedicineDecision

    Second, it should be noted that, during a meeting between the Commission services and Biogen Idec on 16 May 2013, the Commission noted that, in the decisions granting marketing authorisation, no statement was made with regard to data …

    5 May 2021 · 62018TJ0611

  • Judgment of the Court (Fourth Chamber) of 16 March 2023. European Commission and Others v Pharmaceutical Works Polpharma S.A.Decision

    On 9 August 1994, the Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Drugs and Medical Devices, Germany; ‘the BfArM’) granted Fumapharm AG two marketing authorisations concerning two strengths of a …

    16 Mar 2023 · 62021CJ0438

  • Judgment of the Court (Eighth Chamber) of 28 June 2017. Novartis Europharm Ltd v European Commission.Decision

    Under Article 10(1) and (2) of that directive: ‘1. By way of derogation from Article 8(3)(i), and without prejudice to the law relating to the protection of industrial and commercial property, the applicant shall not be required to …

    28 Jun 2017 · 62015CJ0629

  • Judgment of the Court (First Chamber) of 16 October 2008. The Queen, on the application of Synthon BV v Licensing Authority of the DepartmenDecisioninterprets

    In the course of those proceedings, the H igh Court of Justice of England and Wales, Queen’s Bench Division (Administrative Court) decided to stay the proceedings and refer the following questions to the Court for a preliminary …

    16 Oct 2008 · 62006CJ0452

  • Judgment of the Court (Second Chamber) of 14 March 2018. Proceedings brought by Astellas Pharma GmbH.Decisioninterprets

    The request has been made in proceedings brought by Astellas Pharma GmbH with regard to the decision of the Lääkealan turvallisuus- ja kehittämiskeskus (the Finnish Medicines Agency) (‘Fimea’) authorising the marketing of a generic …

    14 Mar 2018 · 62016CJ0557

  • Regulation (EU) 2019/51Law

    … а) заявлението за разрешение е подадено в съответствие с член 10 от Директива 2001/83/ЕО;“ в) параграф 4 се заличава; 9) в член 4 параграф 3 …